Rabeprazole inhibits lung cancer progression by triggering NLRP3/CASP-1/caspase-dependent pyroptosis
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2024.113806 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Chuan Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Thoracic Surgery Department, Qingdao University Affiliated Hospital, Qingdao University Affiliated Hospital Laoshan Campus, Qingdao 266001, China. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Lung Neoplasms, Rabeprazole, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Gastric acid-related diseases could be treated using proton pump inhibitors (PPIs), which have been found to have anti-tumor ability. Rabeprazole is a type of PPI whose effect and mechanism in lung cancer remained to be clarified. METHODS: Lung cancer cells and lung cancer mice were treated with different concentrations of Rabeprazole and then cell proliferation was detected by CCK-8 and colony formation assays. Pyroptosis was assessed by morphological observation and Lactate dehydrogenase (LDH) release assays. Western blot, immunofluorescence and immunohistochemistry were adopted to detect the expressions of GSDMD and NLRP3. Reactive oxygen species (ROS) level, lysosomal damage and autophagic flux were measured by flow cytometry. RESULTS: Rabeprazole suppressed lung cancer cell proliferation and lung tumor growth in mice in a concentration-dependent manner. Lung cancer cells treated with Rabeprazole showed typical pyroptosis morphology and significantly increased LDH release. Rabeprazole upregulated the expression of GSDMD, NLRP3, and cleaved-Caspase 1, but such an effect was partially blocked by Z-LLSD-FMK. In lung cancer cells treated with Rabeprazole and lung cancer mice injected with Rabeprazole, the expressions of GSDMD, NLRP3 and caspase-1 were promoted, ROS-stained cells were increased significantly, lysosomal damage was aggravated, and autophagic flux was noticeably reduced. CONCLUSIONS: Rabeprazole activated NLRP3/caspase 1/GSDMD cascade by promoting ROS accumulation and lysosomal destruction, thereby inducing pyroptosis to fulfill its anti-tumor effect on lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Thoracic Surgery Department, Qingdao University Affiliated Hospital, Qingdao University Affiliated Hospital Laoshan Campus, Qingdao 266001, China.
- Department of Nephrology, Affiliated Hospital of Qingdao University, Qingdao 266001, China.
- Ultrasound Medicine Department, Yantai Zhifu Hospital, Yantai 264010, China.
- Yantai Yuhuangding Medical Imaging Department, Yantai Yuhuangding Hospital, Yantai Yuhuangding Hospital General Hospital, Yantai 264010, China.
- Thoracic Surgery Department, Qingdao University Affiliated Hospital, Qingdao University Affiliated Hospital Laoshan Campus, Qingdao 266001, China. Electronic address: simplelancet@163.com.
Zitieren
APA
Liu, C., Sun, R., Wang, H., Xia, Y., & Wang, Y. (2025). Rabeprazole inhibits lung cancer progression by triggering NLRP3/CASP-1/caspase-dependent pyroptosis. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.113806
Vancouver
Liu C, Sun R, Wang H, Xia Y, Wang Y. Rabeprazole inhibits lung cancer progression by triggering NLRP3/CASP-1/caspase-dependent pyroptosis. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2024.113806
BibTeX
@article{Liu2025,
author = {Liu, Chuan and Sun, Ruolan and Wang, Hanmei and Xia, Yuanhao and Wang, Yongjie},
title = {Rabeprazole inhibits lung cancer progression by triggering NLRP3/CASP-1/caspase-dependent pyroptosis},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2024.113806}
}
EUVIMED